Shannon Winski, PhD
VP, Pharmacology and Toxicology
Shannon Winski joined Cogent in March of 2021 and is responsible for the discovery of new therapeutic agents specifically targeted to tumors that have genetic aberrancies driving their oncogenic potential. Prior to Cogent, Shannon led multiple drug discovery teams from early-stage lead optimization through IND candidate selection as a part of the Array BioPharma Pharmacology department. Additionally, Shannon led the ARRY-614 program from late-stage discovery through the end of Phase I clinical trials. The focus of her personal interests and research has been to understand how preclinical models can be used to inform clinical decision making. Prior to this, in 2001 Shannon worked in the cancer biology department at OSI Pharmaceuticals (previously Gilead Sciences) primarily providing scientific support for development stage cytotoxic and targeted therapeutic candidates. Shannon received her Ph.D. in Pharmacology and Toxicology at the University of Arizona where her research focused on metabolism and toxicity of environmental metals. She completed a post-doctoral fellowship at the University of Colorado studying bioactivation of anti-tumor quinone-based therapeutics. When she isn’t working, Shannon likes to bike, hike, and cook.